• In the media
  • More deals, higher prices lead to greater ant...
Media - published on 17 Mar 2021

More deals, higher prices lead to greater antitrust scrutiny for pharma M&A

Kristen Hallam and Kris Elaine Figuracion for S&P Global Market Intelligence cover the U.S. Federal Trade Commission's efforts to revise the way they, along with Canada, the U.K. and Europe, study the impact of pharmaceutical mergers and acquisitions (M&A).

Get in touch

Back to top |